Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Neoadjuvant Androgen Deprivation Darolutamide and Ipatasertib in Men With Localized High Risk Prostate Cancer

ipatasertib administered in combination with darolutamide; and a phase II neoadjuvant stage in which patients with high risk prostate cancer and loss of PTEN expression in the tumor tissue planning on

  • 0 views
  • 03 Nov, 2021
  • 1 location
A Trial of Ipatasertib in Combination With Atezolizumab (IceCAP)

This is a single centre, proof-of-concept phase I trial of atezolizumab in combination with ipatasertib. There are two parts to this study, the dose escalation phase (Part A) and the dose

AKT
serum bilirubin
aptt
neutrophil count
measurable disease
  • 125 views
  • 22 Apr, 2022
  • 1 location
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients (IPATHER)

This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients with

PIK3CA
immunological adjuvant
bone metastases
taxane
pertuzumab
  • 2 views
  • 28 Feb, 2022
  • 3 locations
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy

and combinations to benefit patients who have failed or are intolerant to 1st line immunotherapy. This study hypothesizes that ipatasertib in combination with taxane (e.g. docetaxel) can be an

  • 0 views
  • 08 Dec, 2021
  • 5 locations
Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (PATHFINDER)

This is a multicenter, open-label, non-comparative, three-arm, phase IIa trial of Ipatasertib (GDC-0068) in combination with non-taxane chemotherapy agents for taxane-pretreated unresectable

carboplatin
capecitabine
taxane
  • 2 views
  • 02 Jul, 2022
  • 13 locations
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

This research is looking to find out if the combination of Ipatasertib with Aromatase inhibitor or Fulvestrant can be an effective treatment for breast cancer.

AKT
endocrine therapy
fulvestrant
cancer treatment
HER2
  • 6 views
  • 12 Feb, 2022
  • 1 location
A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.

A Phase I, Open-Label study designed to assess the pharmacokinetics (PK), safety and tolerability of ipatasertib in Chinese participants. Approximately 20 Chinese participants (12 PK-evaluable

solid tumor
measurable disease
metastatic malignant solid tumor
  • 0 views
  • 15 Jun, 2022
  • 1 location
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

This phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and

  • 0 views
  • 25 May, 2022
  • 1 location
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)

The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).

estrogen receptor
mammogram
fulvestrant
advanced breast cancer
erbb2
  • 39 views
  • 29 Jun, 2022
  • 34 locations
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating

invasive breast cancer
HER2
sentinel node
sentinel lymph node biopsy
adjuvant therapy
  • 0 views
  • 04 Jun, 2022
  • 6 locations